Published in
Sociedade Portuguesa de Pneumologia, Revista Portuguesa de Pneumologia, (14), p. S9-S20, 2008
DOI: 10.1016/s0873-2159(15)30310-x
Links
Tools
Pemetrexed na segunda linha de tratamento do carcinoma do pulmão de não pequenas células – A experiência portuguesa
Journal article published in 2008 by
A. Araújo 
,
F. Barata,
B. Parente,
S. Rego,
E. Teixeira,
M. Melo,
H. Queiroga,
J. Cunha,
J. Duarte,
A. Coelho
,
F. Barata,
B. Parente,
S. Rego,
E. Teixeira,
M. Melo,
H. Queiroga,
J. Cunha,
J. Duarte,
A. Coelho
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Until 2004, docetaxel in monotherapy was the standard for second-line treatment of non-small cell lung cancer (NSCLC). Pemetrexed (P) has shown similar activity in this setting with a better adverse event profile. In Portugal, it was introduced in October of 2004.